Feature | Cath Lab | February 06, 2019

Edwards Lifesciences Recalls Swan-Ganz Catheters Due to Incorrect Assembly

The FDA has identified this as a Class I recall

Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.

Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufactured Dec. 26, 2017, to April 19, 2018 due, to incorrect assembly that reversed the catheter lumens. This recall includes 1,426 devices in the United States.

If the lumens are reversed the clinician may note inaccurate pulmonary artery and central venous pressure values and waveforms. This may result in unintended treatment, which may result in adverse health consequences. The FDA recall notice stated the inaccurate waveforms and pressure values may also misguide a physician during placement of the catheter, increasing the risk of blood vessel perforation. This exposes the patient to a reasonable likelihood of a serious adverse health consequence or death, the FDA said.

These catheters provide a diagnostic tool for physicians to quickly measure blood pressures inside the veins, heart, and arteries and to measure blood flow and blood oxygen levels when used with a compatible cardiac output computer. These catheters are often used in patients who are undergoing complex surgery, such as open heart surgery, or require intensive, invasive monitoring to guide their care during serious illness. 

Lot numbers included in this recall are: 61321177, 61176373, 61227528, 61321254, 61176369, 61176314, 61176370, 61176367, 61176374, 61321241 and 61311580.

On Dec. 12, 2018, Edwards Lifesciences sent affected customers an “Urgent Recall Notification Letter” informing of affected model/lot numbers. The notice requested that customers return any unused units that are currently in their inventory with the affected model and lot numbers. Once returned, replacement product will be shipped to customers at no charge. Edwards Lifesciences pre-populated a “Customer Acknowledgement” form, attached to the notification, with the affected lots and requested that customers follow the instructions on the form to complete the recall process.

The company said there have not been any patient complications reported due to issues with the device. 

The company initiated a full recall Dec. 21, 2018.

Who to Contact for Information or Report Adverse Events

Customers with questions can contact Edward Lifesciences Technical Support Department at (800) 822-9837 option 1.

Healthcare professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Healthcare professionals employed by facilities that are subject to FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.

 

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init